Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications.
Wang X, Venet D, Lifrange F, Larsimont D, Rediti M, Stenbeck L, Dupont F, Rouas G, Garcia AJ, Craciun L, Buisseret L, Ignatiadis M, Carausu M, Bhalla N, Masarapu Y, Villacampa EG, Franzén L, Saarenpää S, Kvastad L, Thrane K, Lundeberg J, Rothé F, Sotiriou C. Wang X, et al. Among authors: rediti m. Nat Commun. 2024 Nov 26;15(1):10232. doi: 10.1038/s41467-024-54145-w. Nat Commun. 2024. PMID: 39592577 Free article.
Integrating molecular imaging and transcriptomic profiling in advanced HER2-positive breast cancer receiving trastuzumab emtansine (T-DM1): an analysis of the ZEPHIR clinical trial.
Rediti M, Fimereli D, Mileva M, Wimana Z, Venet D, Flamen P, Guiot T, de Vries EGE, Schröder CP, Menke-van der Houven van Oordt CW, Maetens M, Majjaj S, Larsimont D, Rothé F, Sotiriou C, Gebhart G. Rediti M, et al. Clin Cancer Res. 2024 Oct 29. doi: 10.1158/1078-0432.CCR-24-1007. Online ahead of print. Clin Cancer Res. 2024. PMID: 39470686
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
Fernandez-Martinez A, Rediti M, Tang G, Pascual T, Hoadley KA, Venet D, Rashid NU, Spears PA, Islam MN, El-Abed S, Bliss J, Lambertini M, Di Cosimo S, Huobe J, Goerlitz D, Hu R, Lucas PC, Swain SM, Sotiriou C, Perou CM, Carey LA. Fernandez-Martinez A, et al. Among authors: rediti m. JAMA Oncol. 2024 May 1;10(5):603-611. doi: 10.1001/jamaoncol.2023.7304. JAMA Oncol. 2024. PMID: 38546612 Free PMC article.
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.
Rediti M, Fernandez-Martinez A, Venet D, Rothé F, Hoadley KA, Parker JS, Singh B, Campbell JD, Ballman KV, Hillman DW, Winer EP, El-Abed S, Piccart M, Di Cosimo S, Symmans WF, Krop IE, Salgado R, Loi S, Pusztai L, Perou CM, Carey LA, Sotiriou C. Rediti M, et al. Nat Commun. 2023 Nov 3;14(1):7053. doi: 10.1038/s41467-023-42635-2. Nat Commun. 2023. PMID: 37923752 Free PMC article. Clinical Trial.
Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22-00.
Joaquin Garcia A, Rediti M, Venet D, Majjaj S, Kammler R, Munzone E, Gianni L, Thürlimann B, Laáng I, Colleoni M, Loi S, Viale G, Regan MM, Buisseret L, Rothé F, Sotiriou C. Joaquin Garcia A, et al. Among authors: rediti m. Clin Cancer Res. 2023 Dec 1;29(23):4908-4919. doi: 10.1158/1078-0432.CCR-23-1267. Clin Cancer Res. 2023. PMID: 37733800
Timing evolution of lobular breast cancer through phylogenetic analysis.
Fimereli D, Venet D, Rediti M, Boeckx B, Maetens M, Majjaj S, Rouas G, Marchio C, Bertucci F, Mariani O, Capra M, Bonizzi G, Contaldo F, Galant C, Van den Eynden G, Salgado R, Biganzoli E, Vincent-Salomon A, Pruneri G, Larsimont D, Lambrechts D, Desmedt C, Brown DN, Rothé F, Sotiriou C. Fimereli D, et al. Among authors: rediti m. EBioMedicine. 2022 Aug;82:104169. doi: 10.1016/j.ebiom.2022.104169. Epub 2022 Jul 23. EBioMedicine. 2022. PMID: 35882101 Free PMC article.
Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.
Venet D, Rediti M, Maetens M, Fumagalli D, Brown DN, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Wang Y, Saura C, Gomez H, Semiglazov VF, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart M, Loi S, Rothé F, Sotiriou C. Venet D, et al. Among authors: rediti m. Clin Cancer Res. 2021 Oct 15;27(20):5607-5618. doi: 10.1158/1078-0432.CCR-21-1317. Epub 2021 Jul 28. Clin Cancer Res. 2021. PMID: 34321278
HER2-Low Breast Cancer: Molecular Characteristics and Prognosis.
Agostinetto E, Rediti M, Fimereli D, Debien V, Piccart M, Aftimos P, Sotiriou C, de Azambuja E. Agostinetto E, et al. Among authors: rediti m. Cancers (Basel). 2021 Jun 5;13(11):2824. doi: 10.3390/cancers13112824. Cancers (Basel). 2021. PMID: 34198891 Free PMC article.
17 results